JP2011522795A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522795A5
JP2011522795A5 JP2011508582A JP2011508582A JP2011522795A5 JP 2011522795 A5 JP2011522795 A5 JP 2011522795A5 JP 2011508582 A JP2011508582 A JP 2011508582A JP 2011508582 A JP2011508582 A JP 2011508582A JP 2011522795 A5 JP2011522795 A5 JP 2011522795A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
molecule
composition according
region
ctla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522795A (ja
Filing date
Publication date
Priority claimed from US12/387,359 external-priority patent/US7915222B2/en
Application filed filed Critical
Publication of JP2011522795A publication Critical patent/JP2011522795A/ja
Publication of JP2011522795A5 publication Critical patent/JP2011522795A5/ja
Pending legal-status Critical Current

Links

JP2011508582A 2008-05-05 2009-05-05 未分類関節炎を有する対象における関節リウマチの発症を予防するための方法 Pending JP2011522795A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US61/050,336 2008-05-05
US12/387,359 2009-05-01
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
PCT/US2009/042761 WO2009137424A1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (2)

Publication Number Publication Date
JP2011522795A JP2011522795A (ja) 2011-08-04
JP2011522795A5 true JP2011522795A5 (enExample) 2012-03-15

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508582A Pending JP2011522795A (ja) 2008-05-05 2009-05-05 未分類関節炎を有する対象における関節リウマチの発症を予防するための方法

Country Status (25)

Country Link
US (3) US7915222B2 (enExample)
EP (2) EP2279206B1 (enExample)
JP (1) JP2011522795A (enExample)
KR (1) KR20110014180A (enExample)
CN (1) CN102037010A (enExample)
AR (1) AR071672A1 (enExample)
AU (1) AU2009244448B2 (enExample)
BR (1) BRPI0912249A2 (enExample)
CA (1) CA2723698C (enExample)
CL (1) CL2009001082A1 (enExample)
DK (1) DK2279206T3 (enExample)
EA (1) EA201001749A1 (enExample)
ES (1) ES2539840T3 (enExample)
HK (1) HK1208230A1 (enExample)
HR (1) HRP20150552T1 (enExample)
HU (1) HUE025256T2 (enExample)
IL (1) IL208691A (enExample)
MX (1) MX2010011503A (enExample)
NZ (1) NZ589020A (enExample)
PL (1) PL2279206T3 (enExample)
PT (1) PT2279206E (enExample)
SI (1) SI2279206T1 (enExample)
TW (2) TWI454278B (enExample)
WO (1) WO2009137424A1 (enExample)
ZA (1) ZA201007914B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CN103906767A (zh) * 2011-10-10 2014-07-02 米迪缪尼有限公司 对类风湿关节炎的治疗
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
US20150232558A1 (en) * 2012-10-30 2015-08-20 Emory University Stimulating bone formation by inhibition of cd28 co-stimulation
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
WO2015164595A1 (en) * 2014-04-25 2015-10-29 Bristol-Myers Squibb Company Use of ctla4 compound for achieving drug-free remission in subjects with early ra
SMT202100467T1 (it) 2015-04-17 2021-09-14 Alpine Immune Sciences Inc Proteine immunomodulatorie con affinità regolabili
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0683793A4 (en) * 1993-01-21 1997-04-09 Univ Georgia Res Found VACCINE AND METHODS FOR PREVENTION AND TREATMENT OF Fescue Toxicity In Herbivorous Animals.
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02012157A (es) * 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2630062C (en) * 2000-07-03 2014-10-14 Bristol-Myers Squibb Company Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
MXPA03006699A (es) * 2001-01-26 2004-05-31 Univ Emory Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
ATE390931T1 (de) * 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
EP1575998A4 (en) * 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
US10092429B2 (en) * 2005-08-22 2018-10-09 Incept, Llc Flared stents and apparatus and methods for delivering them
ATE498358T1 (de) 2005-06-29 2011-03-15 Compumedics Ltd Sensoranordnung mit leitfähiger brücke
PT2253644E (pt) 2005-12-20 2014-01-23 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Similar Documents

Publication Publication Date Title
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
HRP20150552T1 (hr) Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom
RU2505603C2 (ru) Антитело против рецептора il-6
JP2010511388A5 (enExample)
JP2010529957A5 (enExample)
JP2014502955A5 (enExample)
JP2021511826A5 (enExample)
JP2014039548A5 (enExample)
CN110740754A (zh) 一种抗间皮素抗体及其抗体药物缀合物
SI2771031T1 (en) Humanized antibodies that recognize alpha-synuclein
HRP20231066T1 (hr) Bcma (cd269/tnfrsf17) - vezujući proteini
JP2015508757A5 (enExample)
JP2017528419A5 (enExample)
JP2010500005A5 (enExample)
NZ603623A (en) Tcr complex immunotherapeutics
JP2004248677A5 (enExample)
JP2012500020A5 (enExample)
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
JP2019507589A5 (enExample)
PE20131334A1 (es) Anticuerpo igg1 humanizado
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
JP2010533498A5 (enExample)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2011524420A5 (enExample)
JP2016512213A5 (enExample)